One proposed solution to the crisis of antimicrobial resistant (AMR) infections is the development of molecules that potentiate the activity of antibiotics for AMR bacteria, such as methicillin-resistant (MRSA). Rather than develop broad spectrum compounds, we developed a peptide that could potentiate the activity of a narrow spectrum antibiotic, oxacillin. In this way, the combination treatment could narrowly target the resistant pathogen and limit impact on host flora. We developed a peptide, , composed of a binding peptide and a inhibitory peptide conjugated to a branched peptide scaffold, which has modest activity against but exhibits synergy with oxacillin for MRSA both and in a MRSA skin infection model. The low concentration of and sub-MIC concentration of oxacillin necessary for activity suggest that this molecule is a candidate for future medicinal chemistry optimization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554890 | PMC |
http://dx.doi.org/10.1021/acsmedchemlett.7b00200 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!